Journal article icon

Journal article

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Abstract:

PURPOSE: In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance to the anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone. In an attempt to improve the treatment of TP53-defective CLL, a multicenter phase II study was developed to evaluate alemtuzumab and methylprednisolone in combination. PATIENTS AND METHODS: Thirty-...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1200/jco.2011.35.9695

Authors


Expand authors...
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume:
30
Issue:
14
Pages:
1647-1655
Publication date:
2012-05-05
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
URN:
uuid:3ac2af8e-b547-4669-9449-d6d5b9e2ca96
Source identifiers:
324085
Local pid:
pubs:324085

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP